Methods for diagnosing cancer, precancerous state, or susceptibility to other forms of diseases by detecting an acceleration of exon skipping in IRF-1 mRNA
US5643729A · kind A · utility
83Cited by
1References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 24, 1995 |
| Grant date | Jul 1, 1997 |
| Priority date | — |
| Expiry date | Feb 24, 2015 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/158
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention concerns a novel molecular marker useful for diagnosing hematopoietic disorders, including cancers and precancerous conditions. The invention is based on the unexpected discovery that inactivation of the IRF-1 tumor suppressor gene can occur via an altered splicing pattern of the IRF-1 primary transcript. This altered splicing pattern leads to mRNAs lacking exon 2 or exons 2 and 3. The relative amounts of full-length RNA and shortened RNA molecules are significantly different in samples obtained from patients suffering from certain cancers and precancerous conditions as compared to healthy donors.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.